CN110559403A - Traditional Chinese medicine composition for preventing and treating hyperuricemia and preparation method and application thereof - Google Patents
Traditional Chinese medicine composition for preventing and treating hyperuricemia and preparation method and application thereof Download PDFInfo
- Publication number
- CN110559403A CN110559403A CN201910933799.2A CN201910933799A CN110559403A CN 110559403 A CN110559403 A CN 110559403A CN 201910933799 A CN201910933799 A CN 201910933799A CN 110559403 A CN110559403 A CN 110559403A
- Authority
- CN
- China
- Prior art keywords
- parts
- preventing
- chinese medicine
- traditional chinese
- treating hyperuricemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
Abstract
The invention discloses a traditional Chinese medicine composition for preventing and treating hyperuricemia and a preparation method and application thereof, and the traditional Chinese medicine composition is prepared from 1-6 parts of plantain herb, 1-6 parts of purslane, 1-4 parts of glabrous greenbrier rhizome and 1-4 parts of coix seed. The composition provided by the invention is prepared by screening a large amount of raw material compatibility through a large amount of experiments, and animal model experiment results show that: the invention can obviously reduce uric acid of a rat model with hyperuricemia and shows good activity of reducing uric acid. The raw materials are medicinal and edible, so that the safety is good, and no obvious toxic or side effect is found. And can be conveniently prepared into solid preparation medicaments or health care products such as tablets, capsules, solid dispersions, dripping pills and the like with a carrier.
Description
Technical Field
The invention relates to a traditional Chinese medicine composition, in particular to a traditional Chinese medicine composition for preventing and treating hyperuricemia and a preparation method and application thereof.
background
Hyperuricemia is a metabolic syndrome caused by long-term purine metabolic disorder or reduced uric acid excretion, is the most important biochemical basis for gout development, and is the second major metabolic disease following diabetes mellitus, and the incidence rate is high. The division of endocrinology of the Chinese medical society in 2013 in the Chinese expert consensus on hyperuricemia and gout treatment indicates that the incidence of hyperuricemia in China is rising year by year, and particularly, the prevalence of hyperuricemia reaches 5% -23.5% in economically developed cities and coastal areas, and is close to the level of developed countries in the West.
The traditional medicines for treating hyperuricemia at present are western medicines such as allopurinol, benzbromarone and the like, although the effect of reducing the blood uric acid is rapid, the traditional medicines have large toxic and side effects on the liver and the kidney, and cannot be taken for a long time. The market has more health care products with the function of reducing blood uric acid, but few health care products capable of effectively preventing and treating hyperuricemia are available, and the main measures for preventing and treating hyperuricemia of patients with hyperuricemia are still western medicines.
The traditional Chinese medicine considers that the viscera dysfunction and the abnormal transportation and transformation of qi, blood and semen are caused. The spleen fails to transport and transform, and phlegm-turbidity is generated internally, which is transformed from heat to damp-heat phlegm-turbidity internally (excessive production of uric acid in blood); if the liver fails to regulate and defecate, the kidney governs the function of the stool, the excretion of turbid phlegm-damp heat is slow or reduced (the excretion of uric acid in blood is reduced), so that damp-heat phlegm-turbid is accumulated in the interior. In conclusion, the main pathogenesis of the disease is dysfunction of the zang-fu organs and accumulation of damp-heat and phlegm-turbid.
According to the requirements of people suffering from hyperuricemia and the advantages of the traditional Chinese medicine in treating and preventing hyperuricemia, the invention selects a medicinal and edible raw material formula disclosed by the Ministry of health according to the traditional Chinese medicine and traditional Chinese medicine principles and the pathogenesis of hyperuricemia, and is used for preparing functional health-care food or medicine for preventing and treating hyperuricemia.
Disclosure of Invention
The purpose of the invention is as follows: the invention aims to overcome the defects of the prior art and provide a medicine or health-care food which has reliable curative effect and good safety and has good function of preventing and treating hyperuricemia. It is another object of the present invention to provide a method for preparing the same.
The technical scheme is as follows: in order to achieve the above purpose, the invention adopts the technical scheme that:
A traditional Chinese medicine composition for preventing and treating hyperuricemia comprises the following raw materials in parts by weight: 1-6 parts of plantain herb, 1-6 parts of purslane, 1-4 parts of glabrous greenbrier rhizome and 1-4 parts of coix seed.
As a preferred scheme, the traditional Chinese medicine composition for preventing and treating hyperuricemia comprises the following raw materials in parts by weight: 6 parts of purslane, 5 parts of plantain herb, 4 parts of glabrous greenbrier rhizome and 4 parts of coix seed.
The traditional Chinese medicine composition for preventing and treating hyperuricemia is applied to preparation of medicines or health-care products for preventing and treating hyperuricemia.
The preparation method of the traditional Chinese medicine composition for preventing and treating hyperuricemia comprises the following steps:
According to the weight portion, the plantain herb, the purslane, the glabrous greenbrier rhizome and the coix seed are extracted for 1 to 3 times, each time lasts for 0.5 to 3 hours, extracting solutions are combined and concentrated to obtain a concentrate, and then the concentrate is prepared into a pharmaceutical preparation with a pharmaceutically acceptable carrier or a health-care product with a food additive.
Preferably, the preparation method of the traditional Chinese medicine composition for preventing and treating hyperuricemia comprises a decoction method, a reflux method, a continuous reflux method or an ultrasonic extraction method.
Preferably, the preparation method of the traditional Chinese medicine composition for preventing and treating hyperuricemia comprises the steps of tablets, pastilles, capsules, solutions, syrups, suspensions or injections.
The present invention recognizes that hyperuricemia is a disease caused by increased uric acid synthesis or decreased uric acid excretion. The spleen fails to transport and transform, resulting in phlegm-turbidity which is transformed from heat to damp-heat, resulting in excessive production of uric acid. When the liver fails to regulate and defecate, the kidney governs the function of stool, the turbid phlegm-dampness-heat will be slowly excreted or the excretion of uric acid in blood will be reduced. Therefore, the accumulation of damp-heat phlegm-turbidity is the pathological mechanism of the disease, and the main treatment method for treating hyperuricemia of the invention is tonifying spleen and kidney, clearing heat, promoting diuresis and discharging turbidity. Therefore, the invention selects the raw material formula with dual purposes of medicine and food, namely plantain herb, purslane, glabrous greenbrier rhizome and coix seed. Wherein, the plantain herb in the formula is sweet and cold, enters liver, kidney, lung and small intestine channels, clears heat and promotes diuresis, eliminates phlegm, cools blood and detoxifies, so the plantain herb is a monarch drug; the purslane is sour and cold, enters liver and large intestine channels, and is used as a ministerial drug for clearing heat and removing toxicity; coix seed, semen Coicis, sweet, bland and cool, enters spleen, stomach and lung meridians, has the effects of promoting diuresis, eliminating dampness, invigorating spleen, relieving diarrhea, eliminating arthralgia, expelling pus, removing toxic substance and resolving hard mass. Smilax glabra L.has sweet, bland and mild properties, enters liver and stomach meridians, and has the actions of removing toxicity, removing dampness and easing joint movement, so both of them have the action of promoting water and excreting dampness, so they are used as guiding drugs. In the recipe, plantain herb promotes diuresis, removes dampness, clears heat and promotes urination, purslane clears away heat and toxic materials, and coix seed and glabrous greenbrier rhizome promote diuresis, remove dampness, clear away heat and toxic materials. The formula can promote diuresis and eliminate dampness, and clear away heat and toxic materials, so that the effects of tonifying spleen and kidney, clearing away heat, promoting diuresis and discharging turbidity, treating both symptoms and root causes, and preventing and treating hyperuricemia for a long time can be achieved.
Has the advantages that:
The composition provided by the invention is prepared by screening a large amount of raw material compatibility through a large amount of experiments, and animal model experiment results show that: the invention can obviously reduce uric acid of a rat model with hyperuricemia and shows good activity of uric acid. The raw materials are medicinal and edible, so that the safety is good, and no obvious toxic or side effect is found. And can be conveniently prepared into solid preparation medicaments or health care products such as tablets, capsules, solid dispersions, dripping pills and the like with a carrier.
Detailed Description
the present invention is further illustrated by the following examples, which are intended to be purely exemplary and are not intended to limit the scope of the invention, as various equivalent modifications of the invention will occur to those skilled in the art upon reading the present disclosure and fall within the scope of the appended claims.
example 1 blood uric acid lowering experiment
1. Sample preparation
1.1 Positive control: allopurinol tablets;
1.2 traditional Chinese medicine formula extract: decocting 5 parts of plantain herb, 6 parts of purslane, 4 parts of glabrous greenbrier rhizome and 4 parts of coix seed with 10 times of water for 3 times, each time for 30 minutes, combining water extract, and concentrating the water extract at 60 ℃ under reduced pressure to 2g crude drug/ml to obtain a traditional Chinese medicine composition sample extract.
1.3 traditional Chinese medicine control extract: decocting rhizoma Atractylodis 6 parts, herba plantaginis 5 parts, rhizoma Smilacis Glabrae 4 parts and Coicis semen 4 parts with 10 times of water for 3 times (30 min each time), mixing water extractive solutions, and concentrating at 60 deg.C under reduced pressure to 2g crude drug/ml to obtain Chinese medicinal composition sample extract.
2. Effect on hyperuricemic mice
Mice were divided into a blank group, a model group, a positive drug (allopurinol tablet) group and a traditional Chinese medicine formula extract three dose groups (50g each)1，25g·㎏-1，12.5g·㎏-1) Three dose groups of control herbal extracts (50 g. kg.) were administered-1，25g·㎏-1，12.5g·㎏-1) The volume of the drug is 20 ml/kg. The blank and model groups were given equal volumes of saline. Three consecutive days, 1h after the third dose, mice in each group were intraperitoneally injected with hypoxanthine 5.5mg/10g (0.2ml/10g) and subcutaneously injected with uricase inhibitor 0.6mg/10g (0.1ml/10g) except for the blank group. At 1h and 3h after molding, 0.3ml of blood is taken from the mouse, centrifuged, and serum is taken to measure the blood uric acid value.
Table 1 effect on hyperuricemic acid (X ± SD) (n ═ 10) in mice with hyperuricemia
P <0.05 and P <0.01 when compared with blank group; p <0.05, P <0.01 compared to model group.
The results in table 1 show that the blood uric acid level of the mice in the model group is obviously higher than that of the blank group at 1h and 3h, and the significant difference is achieved (P is less than 0.01); the positive medicine group has significant difference (P <0.01) with the model group at 1h and 3h, and the large, medium and small dose groups of the formula group have significant difference (P <0.01, P <0.05)) with the model group at 1h and 3h, and are in a quantity-effect relationship. And the comparison shows that the purslane can obtain better curative effect when being taken as a ministerial drug.
2.3 Effect on rat hyperuricemia
Rats were randomly divided into three dose groups, a blank group, a model group, a positive group (allopurinol tablets) and a traditional Chinese medicine formula extract (50g of kg of rats)-1，25g·㎏-1，12.5g·㎏-1) The volume of the drug is 10 ml/kg. Five consecutive days, 1h after the last administration, except for the blank group, each group was injected subcutaneously with 0.15ml/100g of uricase inhibitor while feeding 1ml/100g of hypoxanthine suspension. Blood is taken for 1h, 3h, 5h and 7h after the model is made to measure the blood uric acid value. The results are shown in Table 2.
Table 2 effect on rat acute hyperuricemia model (X ± SD) (n ═ 8)
p <0.05 and P <0.01 when compared with blank group; p <0.05, P <0.01, compared to model group
The experimental results in table 2 show that the blood uric acid level of the rats in the model group is obviously higher than that of the blank group at each point after model building, and has significant difference (P < 0.01); the blood uric acid in the positions of 1h, 3h, 5h and 7h of the traditional Chinese medicine composition group is lower than that in the model group, and has certain difference (P is less than 0.01, and P is less than 0.05), wherein each point of the large-dose group of the traditional Chinese medicine composition group after the model is made is obviously lower than that in the model group (P is less than 0.01), the blood uric acid in the positions of 1h, 3h, 5h and 7h of the medium-dose group is obviously lower than that in the model group (P is less than 0.01, and P is less than 0.05), and the uric acid value in the positions of 1h, 3h, 5h and 7h of the small-dose group is lower than that in the model. And the comparison shows that the purslane can obtain better curative effect when being taken as a ministerial drug.
The experiment results show that the composition provided by the invention has obvious activity of reducing uric acid, and the traditional Chinese medicine has the advantages of simple raw material composition, weak toxic and side effects and higher safety.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Claims (6)
1. A traditional Chinese medicine composition for preventing and treating hyperuricemia is characterized by comprising the following raw materials in parts by weight: 1-6 parts of plantain herb, 1-6 parts of purslane, 1-4 parts of glabrous greenbrier rhizome and 1-4 parts of coix seed.
2. the traditional Chinese medicine composition for preventing and treating hyperuricemia according to claim 1, which is characterized by comprising the following raw materials in parts by weight: 6 parts of purslane, 5 parts of plantain herb, 4 parts of glabrous greenbrier rhizome and 4 parts of coix seed.
3. The use of the Chinese medicinal composition for preventing and treating hyperuricemia according to claim 1 or 2 in the preparation of a medicament or a health product for preventing and treating hyperuricemia.
4. The preparation method of the traditional Chinese medicine composition with the function of preventing and treating hyperuricemia according to claim 1 or 2,
The method comprises the following steps:
According to the weight portion of claim 1 or 2, the plantain herb, the purslane, the glabrous greenbrier rhizome and the coix seed are extracted for 1 to 3 times, each time lasts for 0.5 to 3 hours, extracting solutions are combined and concentrated to obtain a concentrate, and then the concentrate is prepared into a pharmaceutical preparation with a pharmaceutically acceptable carrier or a health-care product with a food additive.
5. The method for preparing the Chinese medicinal composition for preventing and treating hyperuricemia according to claim 4, wherein the extraction method is a decoction method, a reflux method, a continuous reflux method or an ultrasonic extraction method.
6. The method for preparing a Chinese medicinal composition for preventing and treating hyperuricemia according to claim 4, wherein the preparation comprises tablets, troches, capsules, solutions, syrups, suspensions or injections.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910933799.2A CN110559403B (en) | 2019-09-29 | 2019-09-29 | Traditional Chinese medicine composition for preventing and treating hyperuricemia and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910933799.2A CN110559403B (en) | 2019-09-29 | 2019-09-29 | Traditional Chinese medicine composition for preventing and treating hyperuricemia and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110559403A true CN110559403A (en) | 2019-12-13 |
| CN110559403B CN110559403B (en) | 2022-03-25 |
Family
ID=68783289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910933799.2A Active CN110559403B (en) | 2019-09-29 | 2019-09-29 | Traditional Chinese medicine composition for preventing and treating hyperuricemia and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110559403B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111053859A (en) * | 2020-01-21 | 2020-04-24 | 北华大学 | Traditional Chinese medicine composition for reducing uric acid and preparation method and application thereof |
| CN113317506A (en) * | 2021-06-08 | 2021-08-31 | 广西壮族自治区农业科学院 | Solid beverage for reducing uric acid and preparation method thereof |
| CN115154538A (en) * | 2022-08-02 | 2022-10-11 | 无限极（中国）有限公司 | Traditional Chinese medicine composition with blood uric acid reducing effect and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101204500A (en) * | 2007-12-14 | 2008-06-25 | 南京中医药大学 | Preparation method and composition and Chinese traditional medicine preparation for preventing and curing hyperuricaemia |
| CN103100006A (en) * | 2013-01-30 | 2013-05-15 | 无限极（中国）有限公司 | Chinese herbal medicine composition with uric acid reducing function |
| CN106266463A (en) * | 2016-11-08 | 2017-01-04 | 四圣网络科技（上海）有限公司 | A kind of Chinese medicine composition for treating hyperuricemia and application thereof |
-
2019
- 2019-09-29 CN CN201910933799.2A patent/CN110559403B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101204500A (en) * | 2007-12-14 | 2008-06-25 | 南京中医药大学 | Preparation method and composition and Chinese traditional medicine preparation for preventing and curing hyperuricaemia |
| CN103100006A (en) * | 2013-01-30 | 2013-05-15 | 无限极（中国）有限公司 | Chinese herbal medicine composition with uric acid reducing function |
| CN106266463A (en) * | 2016-11-08 | 2017-01-04 | 四圣网络科技（上海）有限公司 | A kind of Chinese medicine composition for treating hyperuricemia and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 唐英等: "中医药治疗痛风的研究现状", 《世界中医药》 * |
| 齐广瑞等: "宋立群教授治疗痛风验案举隅", 《广西中医药大学学报》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111053859A (en) * | 2020-01-21 | 2020-04-24 | 北华大学 | Traditional Chinese medicine composition for reducing uric acid and preparation method and application thereof |
| CN113317506A (en) * | 2021-06-08 | 2021-08-31 | 广西壮族自治区农业科学院 | Solid beverage for reducing uric acid and preparation method thereof |
| CN115154538A (en) * | 2022-08-02 | 2022-10-11 | 无限极（中国）有限公司 | Traditional Chinese medicine composition with blood uric acid reducing effect and application thereof |
| CN115154538B (en) * | 2022-08-02 | 2023-05-05 | 无限极（中国）有限公司 | Traditional Chinese medicine composition with blood uric acid reducing effect and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110559403B (en) | 2022-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110559403B (en) | Traditional Chinese medicine composition for preventing and treating hyperuricemia and preparation method and application thereof | |
| CN102198262B (en) | Chinese medicine preparation for treating infant rotavirus enteritis and preparation method thereof | |
| CN107362213B (en) | Composition with bowel relaxing function and preparation method thereof | |
| CN113288925A (en) | Traditional Chinese medicine composition for preventing and treating gout | |
| US10653746B2 (en) | Medicament for use in treating gout | |
| CN102657834A (en) | Traditional Chinese medical composition for treatment of alcoholism and preparation process thereof | |
| CN105770715A (en) | Composition with blood sugar lowering function, and preparation method thereof | |
| CN108992600A (en) | A kind of Chinese medicine composition and its application for weight-reducing | |
| CN109820943B (en) | Zhuang medicine preparation for treating gout and preparation method thereof | |
| CN101810337A (en) | Health food containing pseudo-ginseng and ganoderma lucidum and radix astragali | |
| CN107582663B (en) | Uric acid reducing composition | |
| CN101396435B (en) | Traditional Chinese medicine for treating gastrosis and preparation method and use thereof | |
| CN102940850B (en) | Medicine composition for treating gout | |
| WO2013115534A1 (en) | Composition for preventing or treating multiple sclerosis | |
| CN102940750A (en) | Medicine composition for treating gout | |
| CN102274428B (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
| CN111991436A (en) | Application of atractylis lancea aqueous extract in preparation of medicine for preventing, relieving and/or treating hyperuricemia | |
| KR102217732B1 (en) | Composition for preventing and improving the development of premature pseudo-breast | |
| CN114767803B (en) | Dendrobium officinale traditional Chinese medicine composition for down-regulating kidney PDZK1 protein to prevent hyperuricemia, and preparation method and application thereof | |
| CN115607634B (en) | Traditional Chinese medicine composition for preventing and treating hyperuricemia and gout and application thereof | |
| CN102940747A (en) | Medicine composition for treating gout | |
| CN102335386B (en) | Chinese medicinal composition for dispersing qi depression, promoting appetite, removing stagnation and stopping pain and preparation method thereof | |
| CN107335026B (en) | Medicine for treating focal segmental glomerulosclerosis | |
| CN106377651A (en) | Preparation method for extracting pharmaceutical monomer for preventing and treating hyperuricemia and gout from rhizoma smilacis glabrae | |
| KR101794929B1 (en) | Composition comprising Galla Rhois extract for preventing or treating constipation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |